Summary During the course of colon-rectum tumours a number of clinical events may occur in which conventional cytopathology can provide only a partial contribution to the definition of a differential diagnosis, i.e. effusions, distant recurrences and second neoplasias. In the present study we have evaluated whether monoclonal antibody (MoAb) D612, recognising a colon-rectum associated antigen, can be used in this context. To this end, MoAb D612 was employed in combination with a panel of MoAb of well defined tumour specificity in immunocytochemical tests. The immunocytochemical findings obtained were compared with the histological and clinical diagnosis. Of 62 effusions and 40 fine needle aspirates studied, MoAb D612 reactivity correlated with the correct diagnosis in 92.8% of the instances. These results indicate that this reagent may help to improve the current cytopathological diagnosis of colon-rectum tumours by identifying the colonic origin of metastases in patients with unknown primary tumour, differentiating ovarian carcinoma from colon metastases to the ovaries and establishing the presence of a second neoplasia in patients with a previous history other than colon carcinoma.
The increasing availability of monoclonal antibodies to tumour associated antigens (TAA) has led to their use as an adjunct in cytodiagnosis of solid tumours (Ghosh et al., 1983; Johnston et al., 1985; Martin et al., 1988) . This has already resulted in a significant improvement of the diagnosis of serous effusions occurring in patients with unknown primary cancer (Mottolese et al., 1988) .
The diagnosis of metastatic colon-rectum carcinoma relies at present on a multidisciplinary approach. This includes the evaluation of changes in the serum levels of tumour associated markers (Mitchell, 1987) , computed tomography (CT) and echoscans which may be complemented by cytological and more recently by immunocytochemical methods (Bernardino, 1987) using monoclonal antibodies. Despite this complementation a number of clinical situations, i.e. effusions in patients with cryptic primary tumour, distinction between recurrence and second neoplasia, still remain elusive to a correct diagnosis either because of difficulties in cytological identification of tumour origin or because of the lack of highly tumour specific MoAb. In the present study we have evaluated whether the use of the novel MoAb D612 recognising a differentiation antigen of the intestinal tract (Muraro et al., 1989) in immunocytochemical assays can aid as an adjunct to the cytological diagnosis of colon-rectum cancer. Results to be presented demonstrate that, when used in combination with a panel of selected MoAb, this reagent may help to identify: (a) the colonic origin of metastases in patients with occult primary colon rectum cancer; (b) colonrectum metastases to the ovary; and (c) a second neoplasia in patients previously treated for cancer other than colon carcinoma.
Material and methods

Patients
One hundred and two patients evaluated in this study were admitted to the Regina Elena Cancer Institute. For Pleural and peritoneal effusions were collected in sterile conditions using heparin (Liquemin, Roche) as anticoagulant. Cells were separated by centrifugation at 160 g for 10 min, washed three times with Hanks' balanced salt solution (HBSS) (Gibco Lab., Paisley, UK) and resuspended in the same medium at a density of 1 x 106 cellsml-'. When the effusions were highly contaminated by red blood cells, erythrocytes were removed by lysis with TRIS-HN4CI pH 7.4 for 10min at 37°C. Cytospins were obtained using a Shandon cytocentrifuge (Shandon, Runcorn, Cheshire, UK) and used for conventional morphological diagnosis after staining with the Papanicolau and May-Grunwald methods or fixed for 10min in absolute acetone for immunocytochemical evaluation. After fixation cytospins were either immediately processed or stored at -20°C for at least 4 months with no loss of immunological reactivity.
Fine needle aspiration biopsy: procedure and sampling of cell substrates Fine needle aspiration biopsies were performed under local anesthaesia using a 22 gauge needle placed on a 20 ml disposable syringe mounted on a special holder (Cameco 20 ml, Precision Dynamics, Burbank, CA, USA). Lesions of sizes ranging from 1 to 5 cm in diameter were successfully aspirated. The correct needle insertion was assessed by a grid placed on the patient's skin and subsequently the proper needle placement was verified by CT scan. Cellular specimens were immediately smeared onto acid clean glass slides and fixed in 95% ethanol for conventional Papanicolau staining or fixed for 10 min in cold absolute acetone for immunocytochemical evaluation.
Monoclonal and polyclonal antisera
The murine MoAb D612 of the IgG2a isotype to a colorectal specific antigen was produced by using as fusion partner of the non-secreting myeloma murine cell line P3-NSI-Ag4-1 splenocytes of Balb/c mice immunised with a membrane enriched fraction of a moderately differentiated primary colon carcinoma (Muraro et al., 1989) . Other MoAbs (MBrl (Canevari et al., 1983) , OC-125 (Bast et al., 1981; Nouwen et al., 1986) , MOvl9 (Miotti et al., 1987) and KS1/4 (Varky et al., 1984) ) to various TAA used in this study were obtained from different investigators or obtained commercially (B72.3 B6.2 (Colcher et al., 1981) (Sorin Biomedica Saluggia VC Italy) (Table I ) and were used either as purified antibodies (Russo et al., 1983) or as culture supernatants. Their use in diagnostic cytopathology has been extensively described elsewhere (Szpack et al., 1984; Menard et al., 1985; Mottolese et al., 1988) . Fluorescein labelled F(ab)2 fraction of a goat anti-mouse immunoglobulin antiserum was obtained from Sorin Biomedica. Before its use on tissue substrates the antiserum was extensively absorbed with human ABRh+ red blood cells and with insolubilised pooled normal human plasma (Avrameas & Ternynck, 1969 Cell smears sampled by CT-FNA of pulmonary or abdominal masses were fixed for 10 min in absolute acetone and stained using an indirect avidin-biotin complex (ABC) immunoperoxidase method with commercially available reagents (Immucolor, Sorin Biomedica Saluggia VC, Italy) (Hsu et al., 1981) . Slides were incubated overnight with MoAb to various TAA at 4°C in a moist chamber. The enzymatic activity was developed using 3-amino-9-ethylcarbazole (AEC) as chromogenic substrate for 8 min at R/T.
Slides were then rinsed with PBS and counterstained with Mayer's haematoxylin.
Immunoperoxidase stain for CT-FNA substrates was chosen because of the possibility of analysing the cell immunoreactivity in the context of the cellular morphology.
Results
Serologicalfeatures of the MoAb D612 recognising an intestinal differentiation antigen Following extensive immunohistochemical testing (Muraro et al., 1989) MoAb D612 appeared valuable to be tested as an adjunct to diagnostic immunocytology of colon-rectum tumours. The high molecular weight antigen recognised by MoAb D612 is restricted in fact in its distribution to the intestinal epithelium. Of interest to this study the reagent does not have any detectable reactivity with mesothelial cells. Futhermore the antigen is expressed in about 85% of primary colon-rectum carcinomas tested independently of their degree of differentiation and in about 70% of hepatic metastatic lesions. Only a minority of few other primary non colon-rectum tumours displayed such heterogenous reactivity with MoAb D612. This includes about 20% of mucinous tumours from the ovary, and 20% of lung, breast and gastric carcinomas. This range of distribution of reactivity of MoAb D612 has been described in detail previously (Muraro et al., 1989) .
MoAb D612 identifies recurrences of colon-rectum tumours The first part of this study was aimed at determining whether the use of MoAb D612 on different cytological substrates, which included cells harvested from effusions or collected by FNA, could be useful in helping to reach an immunocytochemical diagnosis of colon cancer. To this end cell preparations from 28 patients who had undergone surgery for colon-rectum tumours (disease-free interval ranging from 1 to 6 years) were assayed for the expression of a number of TAA recognised by the panel of MoAb which has already been shown (Mottolese et al., 1988) to help in increasing the diagnostic accuracy of conventional cytopathology of other neoplastic diseases.
As shown in Table II the immunoreactivity of MoAb D612 and the anti-pancarcinoma MoAb B72.3 on various cell preparations indicated an immunocytochemical correlation in about 92.8% of the instances as confirmed by the histopathological diagnosis, which reported 27 cases of metastatic colon-rectum tumours and a primary lung neoplasia.
Only in one case did the reactivity of the lesion with MoAb D612 and B72.3 and the lack of expression of the other TAA suggest the wrong diagnosis of metastatic colon carcinoma which was diagnosed by conventional histopathology as primary lung carcinoma. As reported in the footnote to Table II MoAb D612 helps to identify the origin from colon-rectum of metastatic effusions and non-palpable masses in patients with occult primary cancer MoAb D612 was employed on cell preparations obtained from patients who presented with either effusions or deep tumours of unknown origin. Also in this instance it helps to reach a differential diagnosis when employed in combination with a panel of other MoAb.
As shown in Table III the cell immunoreactivity of 50 effusions studied the cell immunoreactivity correlated with a correct diagnosis of metastatic colon-rectum in six instances, and in 17 cases of ovarian tumours (Figure la) . The immunocytochemical diagnosis failed in two cases of metastatic lung carcinoma and two cases of breast carcinoma. The immunodiagnostic performance of MoAb D612 on 24 FNA Clinical manifestations of colon carcinoma are often delayed 'curative surgery' is high, the symptoms of the recurrences and a disseminated disease to the peritoneum or outside the are often aspecific and contribute minimally to diagnosis. This clinical behaviour raises two main diagnostic problems in the management of colon-rectum carcinoma: (a) the identification of the colonic origin of metastases in patients bearing an occult primary tumour; (b) the correct diagnosis of recurrence in patients previously treated for a colon carcinoma.
Although serial determinations of serum CEA have been reported as an early sign of recurrence of colon carcinoma, this has been shown to be correct only in 58% of the patients (Eisman et al., 1982) . In addition, in patients with a cryptic primary tumour the measurement of CEA levels may be of little diagnostic value. This is due to the low tumour specificity of this marker.
Present radiological (Dixon et al., 1981; Gianola et al., 1984; Waneck et al., 1984) and ultrastructural (Osamura et al., 1985) methods to answer these questions still suffer from gross inaccuracy due to their lack of tumour specificity, or are often not performed on a routine basis.
Although the cytopathological analysis either of metastatic effusions or of FNA of non-palpable lesions detected on CT-scan represents a useful diagnostic tool for the staging and monitoring of patients bearing a colon-rectum cancer, it requires considerable experience and a correct morphological diagnosis of tumour origin, which can be made only in the clinical context of a known primary tumour (Ghosh et al., 1983; Orell & Dowling 1983; Hilborne et al., 1985) .
The application of immunocytochemical methods on different cellular substrates (effusions, fine needle aspirates) could be expected to contribute to an increase in the diagnostic accuracy of the conventional cytopathology in these areas by introducing both the specificity of an antigen-antibody reaction and an objective interpretation of the results.
Attempts in this context have been only partially successful because of the lack of highly tumour specific antibodies Ramaekers et al., 1984; Kyrkou et al., 1985; Johnston et al., 1986) . Ideal reagents in this context should be capable of recognising a tumour associated antigen (TAA) endowed with: (a) high colon cancer specificity; (b) homogeneous expression unrelated to various degrees of tumour differentiation; (c) homogenous expression in metastatic foci independently from their anatomical distribution. Because the high molecular weight TAA recently identified by the murin MoAb D612 appears to fulfil most of these requirements we have employed this antibody in immunocytochemical assays aimed at evaluating whether this reagent is capable of increasing the accuracy of cytodiagnosis of colon-rectum cancer. Because this differentiation antigen is also expressed by about 20% of mucinous ovarian, lung, breast and gastric primary carcinomas, in order to increase the diagnostic accuracy of MoAb D612 this reagent has been employed together with other MoAb which have already been shown to possess a high diagnostic value (Mottolese et al., 1988) when used in combination in detecting breast, lung and ovarian tumours. Otherwise MoAb D612, when tested on 60 effusions metastatic from breast, lung and serous ovarian carcinomas, was negative in 95% of the instances, thus demonstrating a restricted reactivity to primary and metastatic colon-rectum carcinomas. Two clinical features of colon-rectum cancer bearing patients should be recalled. First, as reported by different authors, more than 30% of all metastatic ovarian tumours are actually metastases from colon-rectum carcinomas (Harcourt & Dennis, 1968; Mazur et al., 1984) and unsuspected intestinal tumours are often found in women presenting an ovarian mass initially diagnosed as a primary epithelial ovarian neoplasia (Morrow & Enker, 1984; Lash & Hart, 1987) . In these clinical cases CT-guided FNA of ovarian tumours offers an accurate and relatively atraumatic alternative to surgical biopsy in many instances (Sevin & Nedji, 1983 ) avoiding time-delay and cost of surgery and allowing an adequate treatment of the patient immediately. However, FNA cytology of pelvic tumours is frequently difficult and it is often impossible to establish whether the specimens derive from a primary or metastatic tumour only on the basis of the morphological picture (Linsk & Franzen, 1983) . Primary ovarian carcinomas, in some instances, can display the same cytological appearance as a metastatic adenocarcinoma. Furthermore, patients previously treated for a colon-rectum tumour are known to be at high risk to develop a second neoplasia of mammary, endometrial and pulmonary origin (Cahan et al., 1974; Sugarbaker et al., 1985) . The results of the present study which employed MoAb D612 on different cytological specimens have shown that the addition of this reagent to a number of selected MoAb may help to increase the accuracy of this diagnostic panel of reagents by: (a) identifying the colonic origin of recurrences and of metastases in patients with an occult primary tumour; (b) detecting the presence of a second neoplasia in patients with a previous history other than colon cancer; (c) providing a differential diagnosis between primary ovarian tumour and ovarian metastases from a colon-rectum.
The addition to this diagnostic panel of MoAb recognising mucinous ovarian tumours such as those described recently by Sakakibara et al. (1988) may allow the differential diagnosis between metastatic mucinous colon carcinoma to the ovary from primary mucinous ovarian tumours. Furthermore, the lack of reactivity of MoAb D612 with prostatic cancer (Muraro et al., 1989) , although not evaluated immunocytochemically in the present study, is also likely to allow a differential diagnosis between colon and prostate tumours.
In conclusion, these findings clearly indicate that MoAb D612 may help to improve the diagnosis of colon carcinoma in different clinical situations as shown by the two clinical cases reported, thus allowing the choice of adequate therapeutic strategies of this neoplasia, which represents one of the most common internal malignancies in both sexes. 
